


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Mercy Hospital Jefferson</p> <p>2. P.O. Box 350 Crystal City, MO 63019</p>		<p>In accordance with letter dated November 15, 2017.</p> <p>3. License number: 24-18315-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: July 31, 2024</p> <p>5. Docket No.: 030-14837 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc., Model STM1251; Best Medical International, Inc., Model 2301; Medi-Physics, Inc., Model 6711 (OncoSeed), 6733 (EchoSeed); Theragenics Corporation, Model I-Seed I25.S06)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1 curie total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-18315-01


Docket or Reference Number
030-14837

Amendment No. 35

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation, Model 200 (TheraSeed)) | E. 1 curie total | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at Mercy Hospital Jefferson, Hwy. 61 South, Crystal City, Missouri, 63019.
11. The Radiation Safety Officer (RSO) for this license is Robert F. Turco, Ph.D., DABR.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-18315-01

Docket or Reference Number
030-14837

Amendment No. 35

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

James A. Junker, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Jeffery A. Hardy, M.D.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Timothy R. O'Leary, M.D.

10 CFR 35.300; 10 CFR 35.400

Smita S. Parikh, M.D.

10 CFR 35.100,10 CFR 35.200

Paula M. Leiva, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Bassam A. Roukoz, M.D.

10 CFR 35.200

Carlos Andres Mahia, M.D.

10 CFR 35.100,10 CFR 35.200

Bassem Mikhail, M.D.


10 CFR 35.100,10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-18315-01Docket or Reference Number
030-14837

Amendment No. 35

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 18, 2014 (ML14093B331)
 - B. Letter dated December 30, 2014 (ML15007A466)
 - C. Letter dated February 9, 2015 (ML15041A210)
 - D. Letter dated May 19, 2015 (ML15141A466)
 - E. Letter dated January 12, 2017 (ML17026A262)
 - F. Letter dated June 14, 2017 (ML17170A312)
 - G. Letter dated January 5, 2018 (ML18009A142)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: FEB 15 2018By: Sara A. ForsterSara A. Forster
Region 3